Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy. A Phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.)

Lung Cancer

Volumn 18, Issue 1, 1997, Pages 71-81

  Thomas, P ^a   Kleisbauer, J P ^a   Robinet, G ^b   Clavier, J ^b   Poirier, R ^c   Vernenegre, A ^d   Bonnaud, F ^d   Taytard, A ^e   Paillotin, D ^f   Pommier De Santi, P ^c   Barriere, J R ^g   Pignon, T ^h  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b CHU MORVAN   (France)

^c CENTRE HOSPITALIER   (France)

^d Hopital du Cluzeau   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^g HÔPITAL NORD   (France)

^h TIMONE HOSPITAL   (France)

Author keywords

Carboplatin; Non small cell lung cancer; Radiation therapy; Radiosensitizer

Indexed keywords

CARBOPLATIN; MITOMYCIN; NAVELBINE; VINCA ALKALOID; VINDESINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; RADIATION-SENSITIZING AGENTS; VINBLASTINE; VINDESINE;

EID: 0030841754     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00047-0     Document Type: Article

References (20)

1. Ihde DC. Chemotherapy of lung cancer. N Eng J Med 1992;327:1434-41.
2. Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O'Conell JP, Burke MT, Fiore JJ, Cibas IR, Heelan RT. Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 1986;70:1091-6.
3. Cullen MH. The MIC regimen in non-small cell lung cancer. Lung Cancer 1993;9(2):81-9.
4. Schaake-Koning C, Schuster-Uitterhove L, Hart G, Gonzalez-Gonzalez D. Prognostic factors of inoperable lung cancer by high dose radiotherapy. Int J Radiat Oncol Biol Phys 1983;50:1091-9.
5. Cox JD, Azarnia N, Byhardt RW, Skin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1443-55.
6. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW; Frei EF, Green MR. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. New Engl J Med 1990;323:940-5.
7. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
8. Sause W, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Fisher B, Turrisi A. RTOG 8808 ECOG 4588. Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer. Proc Am Soc Clin Oncol 1994;13:325.
9. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigue P, Schuster-Uitterhoeve L, Sculier JP, Van Zandwijk N, Bartelink H. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl J Med 1992;326:524-30.
10. Trovo M, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;24:11-5.
11. Begg AC, van der Kolk PJ, Emondt J, Bartelink H. Radiosensitization in vitro by cis-diammine (1.1 cyclobutanedicarboxylato) platinum (II) (carboplatin JM8) and ethylene-diammine-malonatoplatinum (II) (JM40). Radiother Oncol 1987;9:157-65.
12. Havemann K, Wolf M, GÜrg C, Hackenbruch E, Pfab R, Gürg K. Preclinical and clinical experience with cisplatin and carboplatin and simultaneous radiation in non-small cell lung cancer. Ann Oncol 1992;3(3):S33-7.
13. Douple EB, Richmond RC, O'Hara JA, Coughlin CT. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1985;12:111-24.
14. Groen HJM, van der Leest AHD, de Vries EGE, Uges DRA, Szabo BG, Mulder NH. Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. Br J Cancer 1995;72:992-7.
15. WHO. Handbook for reporting results of cancer treatment. Geneva: WHO, 1979:48.
16. International Commission on Radiation Units and Measurements. Report no. 29: Dose specification for reporting external beam therapy with photons and electrons. Washington DC: 1978.
17. Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged 'in-use' conditions. J Clin Pharmacol Ther 1991;16:123-9.
18. Smit EF, Willemse PHB, Sleijfer DTh, Uges DRA, Postmus PE, Meijer S, Terheggen PMAB, Mulder NH, de Vries EGE. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. J Clin Oncol 1991;9:100-10.
19. Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Meacci M, Corgna E, Darwish S, Scarcella L, Santucci A, Ballatori E, Tonato M. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian oncology group for clinical research (G.O.I.R.C.). Ann Oncol 1995;6:347-53.
20. Perol M, Guerin JC, Thomas P, Poirier R, Carles P, Robinet G, Kleisbauer JP, Paillotin D, Vergnenegre A, Balmes P, Touron D, Grivaux M, Pham E. For the Groupe Français de Pneumo-Cancérologie. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycine-vindesine in advanced non-small-cell lung cancer. Lung Cancer 1996;14:119-34.